UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: July 30, 2015

(Date of earliest event reported)

 

LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-36562

 

46-2996673

(Commission File Number)

 

(IRS Employer Identification No.)

 

One Landmark Square, Suite 1122
Stamford, CT

 

06901

(Address of Principal Executive Offices)

 

(Zip Code)

 

(203) 653-3880

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(d)

 

On July 28, 2015, the Board of Directors (the “Board”) of Loxo Oncology, Inc. (“Loxo”) appointed Timothy Mayleben as an independent Class I director, a member of the Compensation Committee and a member of the Nominating and Governance Committee, with a term that will expire at Loxo’s annual stockholder meeting in 2018.

 

Mr. Mayleben currently serves as president and chief executive officer of Esperion Therapeutics and has been a member of the board of directors of Esperion since 2010. Prior to joining Esperion, Mr. Mayleben was president, CEO and a director of Aastrom Biosciences. Previously, he was president, chief operating officer and a director of NightHawk Radiology Holdings.  Prior to joining Nighthawk, Tim was chief operating officer of the original Esperion until its acquisition by Pfizer in 2004 for $1.3 billion.  Mr. Mayleben is a board member of several life science companies, including Kaléo Pharma, Lycera Corporation, and Marinus Pharmaceuticals and an advisor to the Wolverine Venture Fund. Mr. Mayleben earned an MBA with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

 

Loxo issued a press release announcing Mr. Mayleben’s appointment to the Board on July 30, 2015, a copy of which is attached to this Form 8-K as Exhibit 99.1.

 

Item 9.01              Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated July 30, 2015

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Loxo Oncology, Inc.

 

 

 

 

 

 

Date: July 30, 2015

By:

/s/ Joshua H. Bilenker, M.D.

 

 

Name: Joshua H. Bilenker, M.D.

 

 

Title: Chief Executive Officer

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated July 30, 2015

 

4


Exhibit 99.1

 

 

Loxo Oncology Appoints Industry Veteran Tim Mayleben to Board of Directors

 

STAMFORD, Conn., July 30, 2015 — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, today announced the appointment of Tim Mayleben to its board of directors. Mr. Mayleben will serve as an independent director and join the nominating and governance committee and the compensation committee.

 

“We are honored to welcome Tim to the Loxo board of directors,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “Tim is a seasoned biotech leader with a proven track record of building and growing life science companies. His judgment and operational expertise will be incredibly valuable as we advance our pipeline of highly-selective targeted cancer therapies through clinical development.”

 

“I am pleased to join the Loxo board of directors and look forward to working with a team that is pioneering a novel approach to the discovery and development of personalized cancer therapeutics,” said Mr. Mayleben. “I’ve had the privilege of working with outstanding drug hunters and development teams in the past and I’m impressed with the decisions made by the Loxo team to rapidly position their pipeline at the cutting edge of precision medicine in cancer.”

 

Mr. Mayleben currently serves as president and chief executive officer of Esperion Therapeutics, and has been a member of the board of directors of Esperion since 2010. Prior to joining Esperion, Mr. Mayleben was president, CEO and a director of Aastrom Biosciences. Previously, he was president, chief operating officer and a director of NightHawk Radiology Holdings. Prior to joining Nighthawk, Mr. Mayleben was chief operating officer of the original Esperion until its acquisition by Pfizer in 2004 for $1.3 billion. Mr. Mayleben is a board member of several life science companies, including Kaléo Pharma, Lycera Corporation, and Marinus Pharmaceuticals and an advisor to the Wolverine Venture Fund. Mr. Mayleben earned an MBA with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

 

###

 

About Loxo Oncology

 

Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential.  Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance.  We leverage the expertise of our partners in academia and industry and our management team’s deep clinical-regulatory experience to deploy focused clinical development strategies in well-defined patient populations. Our goal is to create important new cancer therapies as efficiently as possible to substantially benefit patients. www.loxooncology.com

 

1



 

Contacts

 

Loxo Oncology, Inc.

 

Company:

Jacob S. Van Naarden

Vice President, Corporate Development and Strategy

jake@loxooncology.com

 

Investors:

Peter Rahmer

The Trout Group, LLC

646-378-2973

prahmer@troutgroup.com

 

Media:

Katie Engleman

Pure Communications, Inc.

910-509-3977

katie@purecommunicationsinc.com

 

2